Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boston Scientific Corporation
To gather evidence documenting the performance and clinical outcomes associated with treatment of moderate degenerative lumbar spinal stenosis using the Superion® IDS in patients ≥45 years of age suffering from symptoms of neurogenic intermittent claudication secondary to a confirmed diagnosis of moderate degenerative lumbar spinal stenosis at one or two contiguous levels from L1 to L5.
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male and female patients ≥45 years of age
symptoms of neurogenic intermittent claudication and a confirmed diagnosis of moderate degenerative lumbar stenosis at one or two contiguous levels from L1 to L5
meeting the labeled indications for use of the Superion® Indirect Decompression System (IDS)
You may not be if
not contraindicated as described in the labeled indications for use
Clareo Health | Postmarket Registry for Evaluation of the Superion® Spacer
